Nexstim receives positive feedback from Mind Matters Psychiatry MD on use of their two NBT® systems to treat MDD

- 16/04/2021

Helsinki, Finland: 16 april 2021 – Nexstim Plc (NXTMH:HEX, NXTMS:STO) announces that the company’s SmartFocus® nTMS technology used at Mind Matters Psychiatry MD, US has generated positive feedback from its use in treating patients with depression.

Oladele Adebogun M.D. said, “I was initially introduced to Nexstim by the early outcomes of their registry which showed 50% remission rates in a small number of patients suffering from major depressive disorder. I purchased my first system and have been so impressed with my own patient outcomes that I have added this second system for my patients located in Flower Mound, Texas. I have even been able to successfully treat those patients who failed to respond to TMS on our prior non-Nexstim system. I am proud to contribute to the latest Nexstim treatment outcomes of triple the number of patients where consecutive data from multiple centers have resulted in 47.2 % of patients in remission from MDD at end of treatment and 76.1 % had obtained a clinical response. I know that I am delivering the best care available for my patients when I use Nexstim.”

Further information on Nexstim’s website.